AUTL shows dramatic operational scaling with 496% revenue growth but severe cash burn acceleration and stockholders' equity declining 58% to $178M, indicating urgent funding needs despite commercial progress.
The company is experiencing the classic early commercial-stage biotech challenge of rapidly scaling operations while burning through capital reserves at an unsustainable pace. The massive increase in accounts receivable and inventory suggests AUCATZYL is gaining commercial traction, but the 37% increase in operating cash burn to -$284M annually, combined with cash declining to $104M, creates an immediate funding imperative.
Revenue surged 496% to $10.1M as AUCATZYL gained commercial adoption, with corresponding massive increases in accounts receivable ($24M) and inventory ($33M) reflecting operational scaling. However, this growth came at enormous cost with operating cash burn worsening 37% to -$284M, stockholders' equity plummeting 58% to $178M, and cash reserves declining 54% to $104M. The financial picture shows a company successfully launching its first commercial product but consuming capital at an alarming rate that threatens near-term viability without additional funding.
Receivables surged 160060% — revenue recognized but not yet collected; watch for collection issues or channel stuffing.
Inventory surged 702.5% — growing significantly faster than typical sales pace; potential demand softening or supply chain overcorrection.
Strong top-line growth of 496% — accelerating demand or successful expansion into new markets.
Interest expense surged 294.6% — significant debt increase or rising rates materially impacting earnings.
Equity declined sharply — large losses, buybacks, or write-downs reducing book value significantly.
Cash declined 54.2% — significant cash burn or deployment; verify adequacy of remaining liquidity runway.
Operating cash flow fell 37.5% — earnings quality concerns; investigate working capital changes and non-cash items.
Current assets declined 34% — monitor working capital adequacy and short-term liquidity.
SG&A up 30.5% — significant increase in sales or administrative costs, monitor impact on operating leverage.
Net income declined 30.3% — review whether driven by operations, interest costs, or non-recurring items.
See what changed in your portfolio's filings
500+ US-listed companies analyzed. Language delta, financial analysis, instant signal scoring.
Try Tracenotes free →